drugset
drugset / Trial / NCT07397832

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

NCT07397832 ↗

Phase 2 Recruiting 58 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma

Timeline

Start
2026-01-30
Primary completion
2028-07-30
Completion
2028-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Polatuzumab Vedotin Other / unclassified 1.8 mg/kg —
Subject Rituximab Monoclonal antibody 375 mg/m2 —
Subject Tucidinostat Small molecule 10 mg —
Subject Tucidinostat Small molecule 15 mg —
Subject Tucidinostat Small molecule 20 mg —

Indications

diffuse large B-cell lymphoma